Tarpon Springs, Florida Wednesday, June 4, 2025, 12:00 Hrs [IST] ...

Allarity Therapeutics ( ($ALLR) ) has shared an update. On June 2, 2025, Allarity Therapeutics announced the enrollment of the first patient in ...

Therapeutics announced that the first patient has been enrolled in its new Phase 2 clinical trial protocol of stenoparib for the ...

The trial is expected to generate significant clinical data by late summer 2026. Allarity plans to pursue multiple advantaged ...

Stenoparib continues to demonstrate clinical benefit in heavily pre-treated ovarian cancer, with two patients remaining on treatment for more than 19 months - Initiated utilization of share ...

Stenoparib continues to demonstrate clinical benefit in heavily pre-treated ovarian cancer, with two patients remaining on treatment for more than 19 months TARPON SPRINGS, Fla., May 9 ...

Thomas Jensen, Chief Executive Officer of Allarity Therapeutics, stated: "2024 was a transformational year for Allarity as we made significant progress in advancing stenoparib as a next-generation ...

Stenoparib, a novel dual PARP and tankyrase inhibitor, may offer a more favorable tolerability profile while providing additional therapeutic advantages. Its inhibition of PARP prevents DNA repair ...

Boston (March 6, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a ...

Patient enrollment for Allarity's Phase 2 trial of stenoparib in ovarian cancer is set to begin at U.S. sites. Allarity Therapeutics has announced that it will begin patient enrollment for a new ...

Boston (February 24, 2025)-Allarity Therapeutics, Inc. ("Allarity” or the "Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib-a differentiated ...